Orchestra BioMed Prices $75 Million Offering at $5 per Share
Key Facts
Orchestra BioMed priced an underwritten public offering at $5 per share, selling 15 million shares for expected gross proceeds of $75 million before discounts, commissions and offering expenses, according to the company’s announcement on November 5, 2026. The company had announced the launch of the offering the same day, saying it would issue the shares being offered. The pricing means the size and price of the issuance are now set following the launch announcement, while the stated proceeds remain gross and expected and do not include the effect of an option to purchase additional shares. The company said net proceeds, together with its available cash and cash equivalents, would be used for its clinical programs, research and development, working capital and general corporate purposes. The offering is expected to close on November 9, subject to customary closing conditions.
The offering gives underwriters a 30-day option to purchase up to 2.25 million additional shares at the public offering price per share, less underwriting discounts and commissions. If exercised in full, the option would increase the number of shares sold beyond the base amount of 15 million, but the pricing announcement did not specify final additional proceeds from that possibility. The company appointed Piper Sandler and TD Cowen as joint book-running managers and BTIG as underwriter, and added H.C. Wainwright & Co. as lead manager. The company links the funding to its AVIM Therapy program and global pivotal BACKBEAT trial, as well as its Virtue SAB program and Virtue trial. Targeted uses also include clinical research and development for current or additional candidates, working capital and general corporate purposes.
The new financing represents a planned resource to support clinical programs at a time when the company said cash, cash equivalents and marketable securities totaled $110 million on June 30, 2026. The company estimated then that this balance would provide cash runway into the fourth quarter of 2027. That estimate comes from an earlier disclosure on August 10, while the offering proceeds of $75 million remain gross before discounts and expenses. The company had reported net cash used in operating activities and purchases of fixed assets of $19.6 million in the second quarter of 2026, compared with $15.6 million in the corresponding period of 2025. It attributed the increase mainly to higher research and development costs, including clinical trials, as well as employee and consulting expenses.
On development, the company said the BACKBEAT trial targeted patients with uncontrolled hypertension who were candidates for a dual-chamber pacemaker, and that primary endpoint data would be submitted for consideration as a late-breaking presentation at a major cardiovascular conference in the second quarter of 2027. The company said its priority after enrollment is complete is to finish three-month follow-up, then lock the database and deliver the dataset in the following spring, according to its October 1, 2026 announcement. If results are positive, Medtronic intends to submit marketing applications for the therapy to the U.S. Food and Drug Administration and global regulators. The U.S. pivotal Virtue trial compares the Virtue SAB balloon with the paclitaxel-coated AGENT balloon to treat coronary in-stent restenosis, with planned enrollment of about 740 patients. The pilot SABRE study recorded a target lesion failure rate of 14.3% at three years among all treated patients, according to an intention-to-treat analysis.
Among the near-term events announced by the company is a research and development event in New York on November 12, 2026, to review its AVIM Therapy and Virtue SAB programs. The event gives investors an opportunity to hear updates on the two programs after the announcement that net offering proceeds would be directed to them and their related trials. In the market, the company’s shares closed at $5.62 on November 5, compared with a close of $6 on November 4. The close on the session when the offering was announced was therefore below the previous day’s close, while the announced offering price was $5 per share. The company also said cash proceeds from the sale of Vivasure totaled about $11 million by September 2026, following a $6.1 million milestone payment on September 14 and about $5 million previously received in January.